U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H17FN4O3
Molecular Weight 308.3082
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DELPAZOLID

SMILES

CN1CCN(C=N1)C2=C(F)C=C(C=C2)N3C[C@H](CO)OC3=O

InChI

InChIKey=QLUWQAFDTNAYPN-LLVKDONJSA-N
InChI=1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3/t11-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H17FN4O3
Molecular Weight 308.3082
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

LCB01-0371, an oxazolidinone derivative, shows good activity against Gram-positive pathogens, including Staphylococcus aureus. It is also effective against multidrug-resistant tuberculosis and is currently under clinical development.

Approval Year

PubMed

PubMed

TitleDatePubMed
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
2010 Dec
Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.
2017 Sep
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:48:16 GMT 2025
Edited
by admin
on Mon Mar 31 22:48:16 GMT 2025
Record UNII
43EP6XV33E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
delpazolid [INN]
Preferred Name English
DELPAZOLID
INN  
INN  
Official Name English
LCB-01-0371
Code English
(5R)-3-(3-FLUORO-4-(1-METHYL-5,6-DIHYDRO-1,2,4-TRIAZIN-4(1H)-YL)PHENYL)-5-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE
Systematic Name English
Delpazolid [WHO-DD]
Common Name English
LCB-010371
Code English
LCB01-0371
Common Name English
2-OXAZOLIDINONE, 3-(4-(5,6-DIHYDRO-1-METHYL-1,2,4-TRIAZIN-4(1H)-YL)-3-FLUOROPHENYL)-5-(HYDROXYMETHYL)-, (5R)-
Systematic Name English
(5R)-3-(3-FLUORO-4-(1-METHYL-5,6-DIHYDRO-1,2,4-TRIAZIN-4-YL)PHENYL)-5-(HYDROXYMETHYL)OXAZOLIDIN-2-ONE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 590317
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
Code System Code Type Description
CAS
1219707-39-7
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
FDA UNII
43EP6XV33E
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
NCI_THESAURUS
C166717
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
DRUG BANK
DB13077
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
SMS_ID
300000034072
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
INN
10479
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
PUBCHEM
44205191
Created by admin on Mon Mar 31 22:48:16 GMT 2025 , Edited by admin on Mon Mar 31 22:48:16 GMT 2025
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
MBC99
TARGET ORGANISM->INHIBITOR
Resistant rate of MDR-TB = 0.8%
MIC90
TARGET ORGANISM->INHIBITOR
MIC
TARGET ORGANISM->INHIBITOR
Resistant rate of MDR-TB = 4.2%
MIC90
TARGET ORGANISM->INHIBITOR
A broad spectrum antibiotic.In phase I clinical trials, found to have better safety (milder side effects) than LZD due to its more rapid clearance,88 although final results from a phase IIa EBA study may suggest lower efficacy than both LZD and sutezolid.
Related Record Type Details
ACTIVE MOIETY